Table 3 Treatment-emergent adverse events for all causalities.

From: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males

TEAE (MedDRA preferred term)

Number of AEs (number of subjects with AEs)

RD10046 (N = 30)

NovoRapid (N = 30)

All

6 (6)

1 (1)

Electrocardiogram high voltage

1 (1)

–

Refraction disorder

1 (1)

–

Hyperuricemia

1 (1)

–

Pain in extremity

1 (1)

–

Induration

1 (1)

–

Platelet count increased

1 (1)

–

Blood bilirubin increased

–

1 (1)

  1. MedDRA version 21.1.
  2. N number of subjects studied, TEAE treatment-emergent adverse events, AE adverse event.
Back to article page